ASX:MSBBiotechs
What Mesoblast (ASX:MSB)'s Leadership and Balance Sheet Overhaul Means For Shareholders
In late December 2025 and early January 2026, Mesoblast reshaped its governance and balance sheet, appointing Philip Facchina as non-executive Chair, Lyn Cobley as Audit and Risk Committee Chair, refinancing debt with a new up to US$125 million facility from director and shareholder Dr Gregory George, and filing US$250 million and US$9.48 million shelf registrations.
These moves collectively signal Mesoblast’s progression from development-stage biotech toward a revenue-focused commercial...